148 related articles for article (PubMed ID: 10951137)
1. A comparative study of Fas and Fas-ligand expression during melanoma progression.
Soubrane C; Mouawad R; Antoine EC; Verola O; Gil-Delgado M; Khayat D
Br J Dermatol; 2000 Aug; 143(2):307-12. PubMed ID: 10951137
[TBL] [Abstract][Full Text] [Related]
2. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL.
Zoi-Toli O; Vermeer MH; De Vries E; Van Beek P; Meijer CJ; Willemze R
Br J Dermatol; 2000 Aug; 143(2):313-9. PubMed ID: 10951138
[TBL] [Abstract][Full Text] [Related]
3. Effect of endogenous interleukin-6 on Fas (APO-1/CD95) receptor expression in advanced melanoma patients.
Mouawad R; Antoine EC; Khayat D; Soubrane C
Cytokines Cell Mol Ther; 2000 Sep; 6(3):135-40. PubMed ID: 11140882
[TBL] [Abstract][Full Text] [Related]
4. Frequent downregulation of Fas (CD95) expression and function in melanoma.
Bullani RR; Wehrli P; Viard-Leveugle I; Rimoldi D; Cerottini JC; Saurat JH; Tschopp J; French LE
Melanoma Res; 2002 Jun; 12(3):263-70. PubMed ID: 12140383
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD95 ligand in melanocytic lesions as a diagnostic marker.
Maeda A; Aragane Y; Tezuka T
Br J Dermatol; 1998 Aug; 139(2):198-206. PubMed ID: 9767232
[TBL] [Abstract][Full Text] [Related]
6. Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis.
Terheyden P; Siedel C; Merkel A; Kämpgen E; Bröcker EB; Becker JC
J Invest Dermatol; 1999 Jun; 112(6):899-902. PubMed ID: 10383736
[TBL] [Abstract][Full Text] [Related]
7. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
Hahne M; Rimoldi D; Schröter M; Romero P; Schreier M; French LE; Schneider P; Bornand T; Fontana A; Lienard D; Cerottini J; Tschopp J
Science; 1996 Nov; 274(5291):1363-6. PubMed ID: 8910274
[TBL] [Abstract][Full Text] [Related]
8. Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival.
Neuber K; Eidam B
Onkologie; 2006 Sep; 29(8-9):361-5. PubMed ID: 16974112
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis, Fas and Fas-ligand expression in melanocytic tumors.
Sprecher E; Bergman R; Meilick A; Kerner H; Manov L; Reiter I; Shafer Y; Maor G; Friedman-Birnbaum R
J Cutan Pathol; 1999 Feb; 26(2):72-7. PubMed ID: 10082396
[TBL] [Abstract][Full Text] [Related]
10. Fas and Fas ligand interactions suppress melanoma lung metastasis.
Owen-Schaub LB; van Golen KL; Hill LL; Price JE
J Exp Med; 1998 Nov; 188(9):1717-23. PubMed ID: 9802983
[TBL] [Abstract][Full Text] [Related]
11. Ceramide induces apoptosis in neuroblastoma cell cultures resistant to CD95 (Fas/APO-1)-mediated apoptosis.
Schaefer JT; Barthlen W; Schweizer P
J Pediatr Surg; 2000 Mar; 35(3):473-9. PubMed ID: 10726692
[TBL] [Abstract][Full Text] [Related]
12. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
Shukuwa T; Katayama I; Koji T
Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system.
McGahon AJ; Costa Pereira AP; Daly L; Cotter TG
Br J Haematol; 1998 Jun; 101(3):539-47. PubMed ID: 9633899
[TBL] [Abstract][Full Text] [Related]
14. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
Nevala H; Karenko L; Vakeva L; Ranki A
Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
[TBL] [Abstract][Full Text] [Related]
15. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines.
Klisovic DD; Katz SE; Effron D; Klisovic MI; Wickham J; Parthun MR; Guimond M; Marcucci G
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2390-8. PubMed ID: 12766035
[TBL] [Abstract][Full Text] [Related]
16. Expression of Fas and Fas ligand in uveal melanoma: biological implication and prognostic value.
Anastassiou G; Coupland SE; Stang A; Boeloeni R; Schilling H; Bornfeld N
J Pathol; 2001 Aug; 194(4):466-72. PubMed ID: 11523055
[TBL] [Abstract][Full Text] [Related]
17. Fas ligand reduces viability in primary melanoma short-term cell cultures more than in metastatic melanoma short-term cell cultures.
Hofbauer GF; Hatta N; Daigle I; Hemmi S; Spanaus Schlapbach K; Willers J; Burg G; Simon HU; Dummer R
Dermatology; 2005; 211(4):318-24. PubMed ID: 16286739
[TBL] [Abstract][Full Text] [Related]
18. Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions.
Sikora J; Dworacki G; Zeromski J
Nat Immun; 1998; 16(5-6):244-55. PubMed ID: 11061592
[TBL] [Abstract][Full Text] [Related]
19. Fas and Fas ligand: expression and soluble circulating levels in cutaneous malignant melanoma.
Redondo P; Solano T; VAzquez B; Bauza A; Idoate M
Br J Dermatol; 2002 Jul; 147(1):80-6. PubMed ID: 12100188
[TBL] [Abstract][Full Text] [Related]
20. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
